careers & recruitment People Recent moves of note in and around the biotech and pharma industries. held various leadership roles at Novartis, Turning Point Therapeutics has announced the appointment including development franchise head of of Siegfried Reich (photo) as executive vice president respiratory, development franchise head of and CSO. Reich has over 25 years of pharma and biotech primary care, and global head of clinical experience developing more than 20 drug candidates. He was operations, analytics and regions. most recently senior vice president of research and cofounder of eFFECTOR Therapeutics, and before that was vice Michael Quigley has joined Gilead Sciences president and head of drug discovery at SGX, vice president as senior vice president, research biology. and head of viral and ophthalmic diseases at Pfizer, and He was most recently vice president and director and head of medicinal chemistry at Agouron. head of Bristol-Myers Squibb’s thematic “With a strong commitment to build on the four internally discovered drug research center for tumor microenvironment candidates in our pipeline, we wanted to attract a proven leader and visionary CSO modulation and site head of its Redwood to advance our research strategy,” said Athena Countouriotis, president and CEO of City, California location. Turning Point. “Siegfried is an ideal fit for our team, with deep discovery and novel- target-identification expertise, and a proven track record of developing drug candidates Verana Health has appointed Matthew Roe for difficult-to-drug targets through disciplined discovery and medicinal, structure- and chief medical officer. Roe is a cardiologist fragment-based chemistry.” and clinical researcher who has spent over two decades at the Duke University School of Medicine and the Duke Clinical Research Robert Abraham has been named CSO Therapeutics. He was formerly CSO at Institute, where he focused on research of Vividion Therapeutics. He joins the MorphoSys. initiatives leveraging real-world data and company from Pfizer, where he most patient engagement. recently served as senior vice president and Douglas Fambrough has been appointed to group head, oncology R&D. the board of directors of TScan Therapeutics. Aerie Pharmaceuticals has announced Fambrough is a founder, president and CEO the appointment of Michelle Senchyna Shanghai-based Everest Medicines has of Dicerna Pharmaceuticals. as vice president, clinical development announced the appointment of Kerry and medical affairs. She most recently Blanchard as CEO. He will also join the Precision BioSciences has appointed Geno served as executive director of company’s board of directors. Previously, he Germano, president and CEO of Elucida ophthalmology at Allergan. was operating partner of healthcare private Oncology, to the company’s board of equity firm CBC Group, CSO at Innovent directors. Germano is a 30-year veteran of Halozyme Therapeutics has named Biologics, and senior vice president of the pharma and life sciences industry who Elaine D. Sun senior vice president and Lilly China Drug Development and previously served as president of Intrexon CFO, succeeding Laurie Stelzer, who External Innovation. and held multiple senior roles at Pfizer, resigned to pursue another opportunity. Wyeth and Johnson & Johnson. Sun brings over 20 years of experience in Rodolphe Clerval has been appointed investment banking and the life science chief business officer of Paris-based gene Spark Therapeutics’ cofounder, president industry, most recently serving as CFO and therapy company Horama. Clerval has and head of R&D Katherine High has chief strategy officer at SutroVax. over 18 years of international experience resigned after seven years of leadership. Her in the pharma and biotech industry. Before departure comes two months after Roche Adaptate Biotherapeutics has appointed joining Horama, he was cofounder and chief acquired Spark for $4.3 billion. Mihriban Tuna as CSO. She brings over business officer at Enterome. 15 years of experience in biologics drug Netherlands-based Pharvaris has appointed discovery and development, joining the Troy Cox has been named chairman of Peng Lu to the newly created position of company from F-star, where she was senior Switzerland-based Sophia Genetics after chief medical officer. Lu brings 15 years of vice president of drug discovery. Previously, serving on its board of directors for less than protein therapeutics and small molecule she held key scientific roles at Domantis and a year, taking over from Antoine Duchateau, drug development experience, including GlaxoSmithKline. who will remain on the company’s board. Cox within genetic rare diseases. She previously was formerly CEO of the molecular testing served as vice president, global program lead Relmada Therapeutics has named company Foundation Medicine. Sophia also for rare diseases at Takeda. Thomas C. Wessel executive vice president announced the appointment of Philippe and head of R&D. Wessel previously Menu as chief medical officer. He joins from Enterprise Therapeutics has named David served as chief medical officer at Acorda McKinsey & Company, where he co-led the Morris chief medical officer. Morris joins Therapeutics, at Flex Pharma and more McKinsey Cancer Center consultancy. Enterprise from the Novartis Venture Fund, recently at Asceneuron. where he was a managing director and Markus Enzelberger has been named where he will maintain an appointment Published online: 7 April 2020 entrepreneur-in-residence of Ridgeline as an operating partner. He previously https://doi.org/10.1038/s41587-020-0489-0 506 NATURE BIOTECHNOLOGY | VOL 38 | APRIL 2020 | 506 | www.nature.com/naturebiotechnology.